<DOC>
	<DOCNO>NCT00083343</DOCNO>
	<brief_summary>Candida common fungal pathogen identify hospitalized patient . This study seek enroll adult patient ( 18 year age old ) invasive Candida infection ( involve deep tissue organ ) . The study enroll patient whose site Candida infection bloodstream . Patients fulfill study entry criterion receive single daily dose caspofungin . Caspofungin , intravenous echinocandin antifungal agent , already approve treatment invasive candidiasis . The dosage strength duration caspofungin individualize patient base disease , severity disease extent infection .</brief_summary>
	<brief_title>Caspofungin Treatment Non-blood Candida Infections ( 0991-045 )</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>All patient must least 1 positive culture Candida specie obtain otherwise sterile , nonblood body site within 96 hour study entry . The patient must also clinical evidence Candida infection ( e.g. , oral temperature &gt; 100 degree Fahrenheit , sign inflammation infect site , systolic blood pressure &lt; 90 ) within 96 hour study entry . The patient must least 18 year old , woman child bear potential , must negative serum urine pregnancy test sensitive 25 IU HCG prior enrollment . Patients whose site Candida infection bloodstream .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>